Gabarapl2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
| GABARAPL2 Protein |
|---|
| Protein Name | GATE-16 (GABA Receptor-Associated Protein-Like 2) |
| Gene | [GABARAPL2](/genes/gabarapl2) |
| UniProt ID | O95167 |
| PDB ID | 2L8J, 2NNS |
| Molecular Weight | 13.7 kDa |
| Subcellular Localization | Cytoplasm, Autophagosome, Golgi, ER |
| Protein Family | ATG8 family, ATL3 family |
| Chromosomal Location | 16p13.3 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Hereditary Spastic Paraplegia |
GABARAPL2 (GATE-16) is a member of the ATG8 family of ubiquitin-like proteins involved in autophagosome maturation, cargo selection, and selective autophagy. Originally identified as a protein interacting with GABA(A) receptors, GATE-16 has emerged as a critical regulator of autophagy in neurons and a key player in neurodegenerative disease pathogenesis.
| Domain |
Position |
Function |
| Ubiquitin-like fold |
1-117 |
ATG8 family core structure |
| N-terminal helical domain |
1-30 |
Membrane interaction |
| LIR (LC3-Interacting Region) |
42-45 |
Autophagy receptor binding |
| GABARAPL2-specific insertion |
80-95 |
Protein-protein interactions |
| C-terminal glycine |
117 |
Lipidation site (ATG3 conjugation) |
The 3D structure reveals a compact ubiquitin-like fold with unique surface features conferring specificity for distinct autophagy receptors.
GABARAPL2 exhibits broad but specific expression:
- Brain: High expression in cerebral cortex, hippocampus (CA1-CA3, dentate gyrus), basal ganglia, and cerebellum
- Neurons: Particularly abundant in pyramidal neurons and cerebellar Purkinje cells
- Glia: Moderate expression in astrocytes, microglia
- Peripheral tissues: Heart, liver, skeletal muscle, pancreas
- Subcellular: Cytosolic and membrane-associated pools
GABARAPL2 participates in multiple stages of autophagy:
- Autophagosome formation: Recruitment of ATG proteins to phagophore
- Cargo recognition: LIR-mediated binding to autophagy receptors
- Membrane fusion: Facilitation of autophagosome-lysosome fusion
- Selective autophagy: Recognition of ubiquitinated cargo
- Receptor clustering: Regulates GABA(A) receptor surface expression
- Synaptic inhibition: Modulates inhibitory synaptic transmission
- Receptor endocytosis: Controls receptor turnover at synapses
- Protein quality control: Clearance of misfolded proteins
- Organelle maintenance: Mitochondrial and ER quality control
- Stress response: Nutrient deprivation and oxidative stress adaptation
GABARAPL2 undergoes post-translational modification:
- ATG7 (E1-like): Activates GABARAPL2
- ATG3 (E2-like): Conjugates GABARAPL2 to PE
- ATG5-ATG12/ATG16L1: E3-like complex enhances lipidation
| Receptor |
LIR Domain |
Cargo |
Function |
| p62/SQSTM1 |
LIR cluster |
Ubiquitinated proteins |
Aggregate clearance |
| OPTN |
LIR motif |
Ubiquitinated mitochondria |
Mitophagy |
| NDP52 |
LIR motif |
Bacteria |
Xenophagy |
| NBR1 |
LIR motif |
Protein aggregates |
Aggresome clearance |
- mTORC1 inhibition: Activates GABARAPL2 function
- AMPK activation: Phosphorylates ATG14L, promotes autophagy
- Nutrient sensing: Amino acid starvation triggers GABARAPL2 lipidation
- Amyloid clearance: GABARAPL2-mediated autophagy clears Aβ plaques
- Tau pathology: Impaired autophagy contributes to tau accumulation
- Synaptic function: Altered GABAergic signaling in AD
- Neuronal survival: GABARAPL2 protects against Aβ toxicity
- α-Synuclein clearance: GABARAPL2-dependent selective autophagy
- Mitochondrial quality control: Mitophagy of damaged mitochondria
- Lewy body formation: Impaired autophagic clearance
- Dopaminergic neuron protection: GATE-16 neuroprotective in PD models
- Mutant huntingtin clearance: Autophagy induction reduces mHTT
- Aggregate removal: Enhanced clearance of polyglutamine aggregates
- Neuronal protection: Improved motor function in models
- TDP-43 clearance: Selective autophagy of TDP-43 aggregates
- SOD1 clearance: Mutant SOD1 removal
- Axonal transport: Autophagosome trafficking in motor neurons
- ATG16L1 interactions: GABARAPL2 in membrane trafficking
- ER morphology: Role in ER shaping
| Approach |
Mechanism |
Status |
| mTOR inhibitors |
Activate autophagy |
FDA approved |
| AMPK activators |
Energy stress |
Clinical trials |
| ATG gene therapy |
Overexpression |
Preclinical |
| GABARAPL2 modulators |
Direct targeting |
Discovery |
- Rapamycin: mTORC1 inhibition
- Metformin: AMPK activation
- Carbamazepine:ophagy induction
- Lithium: GSK3β inhibition, autophagy
- AAV-GABARAPL2: Viral vector delivery
- CRISPR activation: Endogenous GABARAPL2 upregulation
- Combination approaches: GABARAPL2 + TFEB
- GABARAPL2 levels: CSF and blood markers
- Lipidation status: GABARAPL2-II/LC3-II ratios
- Autophagy flux: Sequential degradation measurements
- Gabarapl2⁻/⁻ mice: Viable, subtle neurological phenotypes
- Conditional knockout: Neuron-specific deletion causes deficits
- Developmental studies: Essential for neural development
- GABARAPL2 overexpression: Neuroprotection in AD/PD models
- GABARAPL2 mutants: Disease-associated variants
- Humanized models: Studying human-specific functions
- GABARAPL2 is essential for selective autophagy
- LIR-mediated cargo recognition is crucial
- GABARAPL2 has non-redundant functions from LC3
- What determines GABARAPL2 specificity for cargo?
- How is GABARAPL2 regulated in neurons?
- Can selective autophagy be therapeutically targeted?
- Cryo-EM: GABARAPL2-receptor complexes
- Single-cell proteomics: Cell-type specific autophagy
- Optogenetics: Light-controlled autophagy
The study of Gabarapl2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.